Expanded Access Program of Zidesamtinib (NVL-520) for Patients With Advanced ROS1+ NSCLC or Other ROS1+ Solid Tumors

NCT06797362 · clinicaltrials.gov ↗

AVAILABLE

Status

INDUSTRY

Sponsor class

Conditions

Non Small Cell Lung Cancer
ROS1-positive Non-Small Cell Lung Cancer (NSCLC)

Interventions

DRUG: NVL-520

Sponsor

Nuvalent Inc.